Investigator‐initiated trials run by clinical trial networks provide net economic benefits to health systems
Delivery of optimal health care relies on evidence from randomised clinical trials, among other factors, to inform best practice. While the generation of such evidence requires resources, both national and international assessments of health and economic benefits resulting from medical research indicate large returns on investment.1,2,3 In Australia, during the decade 2006–2015, more than 10 000 clinical trials were conducted through Australian clinical trials networks (CTNs), including more than 5 million participants, ranking Australia in the top tier of clinical trial activity.4 Industry‐funded clinical trials accounted for an estimated $930 million of the total $1.1 billion spent annually on clinical trials, with National Health and Medical Research Council (NHMRC) funding accounting for about $164 million annually.4 While the proportion of funding for non‐industry‐sponsored investigator‐initiated clinical trials (IITs) is relatively small, these studies account for more than half of Australia’s clinical trial activity.4 This study funding balance is similar to what is reported elsewhere.5
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Lateral Economics. The economic value of Australia’s investment in health and medical research: reinforcing the evidence for exceptional returns, October 2010. https://lateraleconomics.com.au/wp-content/uploads/2014/02/The-Ec-Value-of-Austs-Invmt-in-Med-Research.pdf (viewed Dec 2020).
- 2. Australian Society for Medical Research. Extrapolated returns from investment in medical research future fund (MRFF). Canberra: Deloitte Access Economics, 2014. https://asmr.org.au/wp-content/uploads/library/ASMR%20Deloittee%20Report_MRFF.pdf (viewed Dec 2020).
- 3. Johnston SC, Rootenberg JD, Katrak S, et al. Effect of a US National Institutes of Health programme of clinical trials on public health and costs. Lancet 2006; 367: 1319–1327.
- 4. Askie LM, Hunter KE, Berber S, et al. The clinical trials landscape in Australia. 2005–2016. Sydney: Australian New Zealand Clinical Trials Registry, 2017. http://www.anzctr.org.au/docs/ClinicalTrialsInAustralia2006-2015.pdf (viewed Dec 2020).
- 5. Hakoum MB, Jouni N, Abou‐Jaoude EA, et al. Characteristics of funding of clinical trials: cross‐sectional survey and proposed guidance. BMJ Open 2017; 7: e015997.
- 6. Simes J, Morton R. Strategies for supporting trials of high value. ACTA 2016 National Summit; Melbourne (Australia), Nov 24, 2016. http://www.clinicaltrialsalliance.org.au/wp-content/uploads/2016/12/1-ACTA2016_Simes.pdf (viewed Dec 2020).
- 7. Pham CT, Karnon JD, Middleton PF, et al. Randomised clinical trials in perinatal health care: a cost‐effective investment. Med J Aust 2017; 207: 289–293. https://www.mja.com.au/journal/2017/207/7/randomised-clinical-trials-perinatal-health-care-cost-effective-investment
- 8. Australian Clinical Trials Alliance, National Health and Medical Research Council. Report on the activities and achievements of clinical trials networks in Australia 2004–2014. Melbourne: NHMRC, 2015. https://www.australianclinicaltrials.gov.au/sites/default/files/files/Report%20on%20the%20Activities%20%20Achievements%20of%20Clinical%20Trials%20Networks%20in%20Australia.pdf (viewed Dec 2020).
- 9. Australian Commission on Safety and Quality in Health Care. Economic evaluation of investigator‐initiated clinical trials conducted by networks. Final report. Sydney: ACSQHC, 2017. https://www.safetyandquality.gov.au/publications-and-resources/resource-library/economic-evaluation-investigator-initiated-clinical-trials-conducted-networks-final-report (viewed Dec 2020).
- 10. Guthrie S, Hafner M, Bienkowska‐Gibbs T, Wooding S. Returns on research funded under the NIHR Health Technology Assessment (HTA) Programme: economic analysis and case studies [Doc. No. RR‐666-DH]. Santa Monica, CA: RAND Corporation, 2015. https://www.rand.org/pubs/research_reports/RR666.html (viewed Dec 2020).
- 11. Bentley C, Cressman S, van der Hoek K, et al. Conducting clinical trials‐costs, impacts, and the value of clinical trials networks: a scoping review. Clin Trials 2019; 16: 183–193.
- 12. Hornberger J, Eghtesady P. The cost–benefit of a randomized trial to a health care organization. Control Clin Trials 1998; 19: 198–211.
The joint ACTA/ACSQHC Working Group (article authors): Rhiannon Tate (Monash University, VIC), Emma Britton (Australian Commission on Safety and Quality in Healthcare [ACSQHC], NSW), Steve Webb (Monash University, VIC), Charlotte Ramage (Quantium Health, VIC), Julie Bernhardt (Florey Institute of Neuroscience and Mental Health, VIC), Alan Cass (Menzies School of Health Research, NT), Craig J French (Western Health, VIC), Katie Groom (University of Auckland, New Zealand), Robert Herkes (ACSQHC, NSW), Catherine Katz (ACSQHC, NSW), Ben W Mol (University of Adelaide, SA), R John Simes (NHMRC Clinical Trials Centre, NSW), Neil Sonderlund (Quantium Health, VIC), Belinda E Butcher (WriteSource Medical and UNSW Sydney, NSW), and John R Zalcberg (Monash University, VIC). The Australian Clinical Trials Alliance (ACTA) acknowledges operational funding from the Australian Government’s Medical Research Future Fund. Ben Mol reports an investigator grant (GNT1176437) from the National Health and Medical Research Council (NHMRC).
Charlotte Ramage reports consulting fees from Australian Clinical Trials Alliance during the conduct of the study. Julie Bernhardt reports personal fees from Dart Neuroscience, outside the submitted work. Ben Mol reports personal fees from Guerbet; he has received research funding from Guerbet and Merck, has been a member of the ObsEva advisory board and holds stock options for ObsEva, outside the submitted work. Neil Soderlund reports consultancy fees from Australian Commission on Safety and Quality in Health Care during the conduct of the study. John Zalcberg reports investments in GW Pharmaceuticals, Aimmune, Vertex, Alnylam, BioMarin, Gilead, Moderna, Concert Pharmaceuticals, Madrigal Pharmaceuticals, MyoKardia, Orphazyme, CRISPR, Myovant, Frequency Therapeutics, Global Blood Therapeutics, uniQure, Sangamo Biosciences, Acceleron, Zogenix; grants and personal fees from Pfizer; grants, personal fees and non‐financial support from Merck Serono; grants and personal fees from Specialized Therapeutics; personal fees from Targovax, Halozyme, Gilead Sciences, Sirtex Medical, and Lipotek; personal fees and non‐financial support from MSD; grants from Bayer, Roche, BMS, Baxalta/Shire, Lilly, and Boehringer‐Ingelheim; grants and non‐financial support from AstraZeneca; non‐financial support from Deciphera, outside the submitted work. He is Chair at Australian Clinical Trials Alliance, and Co‐Chair at National Oncology Alliance and at All.Can Australia.